Abstract
Exam 2: Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have